A Concise Synthesis of a beta-Lactamase Inhibitor

Department of Process Research, Merck and Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, USA.
Organic Letters (Impact Factor: 6.32). 09/2011; 13(20):5480-3. DOI: 10.1021/ol202195n
Source: PubMed

ABSTRACT MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics. Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N-H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A recent report suggests that the reaction of dimethylsulfoxonium methylide with esters does not produce a chain-extended sulfur ylide as previously reported, but rather affords the corresponding carboxylate salt. We have investigated this assertion by using a combination of ab initio molecular orbital calculations, spiking studies, and isotopic labeling. The formation of carboxylate is unambiguously demonstrated to arise through hydrolysis involving adventitious water, principally derived from moisture in commercial trimethylsulfoxonium chloride. Careful vacuum drying of this reagent diminishes the competing hydrolytic pathway resulting in higher yields for the chain-extension reaction than previously reported.
    European Journal of Organic Chemistry 07/2013; 2013(20). DOI:10.1002/ejoc.201300526 · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The enantioselective synthesis of two novel cyclopropane-fused diazabicyclooctanones is reported here. Starting from butadiene monoxide, the key enone intermediate 7 was prepared in six steps. Subsequent stereoselective introduction of the cyclopropane group and further transformation led to compounds 1a and 1b as their corresponding sodium salt. The great disparity regarding their hydrolytic stability was rationalized by the steric interaction between the cyclopropyl methylene and urea carbonyl. These two novel β-lactamase inhibitors were active against class A, C, and D enzymes.
    ACS Medicinal Chemistry Letters 10/2014; 5(10):1143-7. DOI:10.1021/ml500284k · 3.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The continued emergence of multi-drug-resistant bacteria is a major public health concern. The identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections. This review lists the 22 new antibiotics launched since 2000 and details the two first-in-class antibiotics, fidaxomicin (1) and bedaquiline (2), launched in 2011 and 2012, respectively. The development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of the 49 compounds and 6 β-lactamase/β-lactam combinations in active clinical development are discussed, as well as compounds that have been discontinued from clinical development since 2011. New antibacterial pharmacophore templates are also reviewed and analyzed. Keywords: antimicrobial resistance; antibiotic; clinical trials; drug development; drug discovery; natural product
    The Journal of Antibiotics 09/2013; 66(10):571-591. DOI:10.1038/ja.2013.86 · 2.04 Impact Factor